Form 4: Director Dexter Exits SONN, Converts Equity to HSI

Sonnet BioTherapeutics Director Susan Dexter reported the disposition of 9,643 common shares, converting them into Hyperliquid Strategies Inc. stock and CVRs following a business combination.

Summary

• Susan Dexter, a Director of Sonnet BioTherapeutics Holdings, Inc. (SONN), reported the disposition of 9,643 shares of common stock on December 2, 2025.
• This transaction resulted in her beneficial ownership of SONN common stock becoming 0.
• The disposition was a result of a Business Combination Agreement (BCA) dated July 11, 2025.
• Under the BCA, Sonnet BioTherapeutics Holdings, Inc. merged into TBS Merger Sub Inc., with Sonnet surviving as a direct wholly-owned subsidiary of Hyperliquid Strategies Inc (HSI).
• The 9,643 shares comprised 8,000 restricted stock units (RSUs) granted on July 11, 2025, which vested upon the merger, and 1,643 previously vested RSUs.
• Each RSU was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• All share amounts reflect a 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a director's exit from a company's stock might seem negative, this is a mandatory reporting of a transaction resulting from a pre-announced merger, which is a strategic event. The conversion into shares of the acquiring entity (HSI) and CVRs provides a new investment vehicle for the former SONN equity holder. The prior reverse stock splits are a historical negative for SONN, but the merger itself could be seen as a positive strategic move.

Positives

• The transaction indicates the successful completion of a business combination, potentially offering new growth avenues under Hyperliquid Strategies Inc. (HSI).
• The conversion of RSUs into HSI common stock and CVRs provides liquidity and potential future value for the reporting person.

Negatives

• The reporting person no longer holds direct beneficial ownership in Sonnet BioTherapeutics Holdings, Inc. common stock, indicating a full exit from SONN equity.
• The significant reverse stock splits (1:22 and 1:8) prior to the merger could indicate past stock performance challenges for Sonnet BioTherapeutics.

Future Outlook

The filing indicates the completion of a business combination where Sonnet BioTherapeutics Holdings, Inc. became a wholly-owned subsidiary of Hyperliquid Strategies Inc. (HSI), suggesting a strategic shift and integration into HSI's operations. The future outlook for the former SONN equity holders now depends on the performance of HSI common stock and the value realized from the Contingent Value Rights.

Industry Context

This transaction reflects a consolidation trend common in the biotechnology and pharmaceutical sectors, where smaller companies like Sonnet BioTherapeutics are acquired by larger entities or merged into new structures to leverage synergies, access capital, or streamline operations. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech mergers to bridge valuation gaps and provide former shareholders with potential upside tied to future milestones or performance.

Stakeholder Impact

• Shareholders of Sonnet BioTherapeutics Holdings, Inc. (SONN) have had their equity converted into shares of Hyperliquid Strategies Inc. (HSI) and Contingent Value Rights (CVRs), fundamentally changing their investment vehicle and future prospects.
• Employees of Sonnet BioTherapeutics Holdings, Inc. are now part of Hyperliquid Strategies Inc. (HSI), potentially impacting their roles, benefits, and corporate culture.

Next Steps

• Integration of Sonnet BioTherapeutics Holdings, Inc. into Hyperliquid Strategies Inc. (HSI) operations.
• Realization of value from Contingent Value Rights (CVRs) for former SONN shareholders.

Key Dates

Keywords

Sonnet BioTherapeutics, SONN, Hyperliquid Strategies Inc, HSI, Susan Dexter, Form 4, Insider Trading, Beneficial Ownership, Business Combination, Merger, Restricted Stock Units, RSU, Contingent Value Right, CVR, Reverse Stock Split